Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-22T08:18:25.311Z Has data issue: false hasContentIssue false
  • English
  • Français

Serotonergic and Noradrenergic Function in Pathological Gambling

Published online by Cambridge University Press:  07 November 2014

Concetta M. DeCaria ,
Tomer Begaz  and
Eric Hollander
Get access Rights & Permissions [Opens in a new window]

Abstract

Research on pathological gambling has begun to demonstrate the significant pathophysiologic role of several neurotransmitter systems in this disorder. Challenge studies with various pharmacologic agents have suggested the importance of potential dysregulation of the serotonergic system in pathological gambling, as this system is linked to dysfunction in behavioral initiation and inhibition. In addition, the noradrenergic system has been associated with mediation of arousal, increases of which are manifested by pathological gamblers. The interactions between these and other neurotransmitter systems, as well as the similarities between pathological gambling and other behavioral disorders, may provide important clues for pharmacologic intervention.

Type
Feature Articles
Information
CNS Spectrums , Volume 3 , Issue 6: Pathological Gambling , June 1998 , pp. 38 - 47
Copyright
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
2.World Health Organization. International Statistical Classification of Diseases and Related Health Problems. Geneva: World Health Organization.Google Scholar
3.Livingston, J. Compulsive Gamblers: Observations on Action and Abstinence. New York, NY: Harper Torchbooks; 1974.Google Scholar
4.Custer, RL, Custer, LF. Characteristics of the recovering compulsive gambler: a survey of 150 members of Gamblers Anonymous. Presented at the Fourth Annual Conference on Gambling; December 1978; Reno, Nev.Google Scholar
5.Ciarrochi, J, Richardson, R. Profile of compulsive gamblers in treatment: update and comparisons. J Gambling Behav. 1989;5:53–65.Google Scholar
6.Phillips, DP, Welty, WR, Smith, MM. Elevated suicide levels associated with legalized gambling. Suicide Life Threat Behav. 1997:27:373–378.CrossRefGoogle ScholarPubMed
7.Commission on the Review of the National Policy Toward Gambling. Gambling in America. Washington, DC: US Government Printing Office; 1976.Google Scholar
8.Culleton, RP. A Survey of Pathological Gamblers in the State of Ohio. Columbus, Ohio: Report prepared for the Ohio Lottery Commission; 1985.Google Scholar
9.Culleton, RP, Lang, MH. The Prevalence Rate of Pathological Gambling in the Delaware Valley in 1984. Camden, NJ: Forum for Policy Research and Public Service, Rutgers University; 1985.Google Scholar
10.Volberg, RA. Estimating the prevalence of pathological gambling in the United States. Presented at the Eighth International Conference on Risk and Gambling; August 1990; London, UK.CrossRefGoogle Scholar
11.Volberg, RA, Steadman, HJ. Refining prevalence estimates of pathological gambling. Am J Psychiatry. 1988;145:502–505.Google ScholarPubMed
12.Volberg, RA, Steadman, HJ. Prevalence estimates of pathological gambling in New Jersey and Maryland. Am J Psychiatry. 1989;146:1618–1619.Google Scholar
13.Volberg, RA. Gambling and Problem Gambling in New York: A 10 Year Replication Survey, 1986 to 1996. Report to the New York Council on Problem Gambling; 1996.Google Scholar
14.Daghestani, AM, Elenz, E, Crayton, JW. Pathological gambling in hospitalized substance abusing veterans. J Clin Psychiatry. 1996;58:360–363.Google Scholar
15.Feigelman, W, Kleinman, PH, Lesieur, HR, Millman, RB, Lesser, ML. Pathological gambling among methadone patients. Drug Alcohol Depend. 1995;39:75–81.CrossRefGoogle ScholarPubMed
16.Haberman, PW. Drinking and other self-indulgences: complements or counter attractions? Int J Addict. 1969;4:157–167.CrossRefGoogle Scholar
17.Lesieur, H, Blume, SB, Zoppa, RM. Alcoholism, drug abuse, and gambling. Alcohol Clin Exp Res. 1986;10:33–38.CrossRefGoogle Scholar
18.Spunt, B, Lesieur, J, Hunt, D, Cahill, L. Gambling among methadone patients. Int J Addict. 1995;30:929–962.Google Scholar
19.McCormick, RA, Russo, AM, Ramirez, LF, Taber, JI. Affective disorders among pathological gamblers seeking treatment. Am J Psychiatry. 1984;141:215–218.Google ScholarPubMed
20.Linden, RD, Pope, HG, Jonas, JM. Pathological gambling and major affective disorders: preliminary findings. J Clin Psychiatry. 1986;47:201–203.Google ScholarPubMed
21.Lesieur, HR. The female pathological gambler. In: Eadington, WR, ed. Gambling Studies: Proceedings of the Seventh International Conference on Gambling and Risk-Taking. Reno, Nev: University of Nevada; 1988.Google Scholar
22.Specker, SM, Carlson, GA, Christenson, GA, Marcotte, M. Impulse control disorders and attention deficit disorder in pathological gamblers. Ann Clin Psychiatry. 1995;7:175–179.CrossRefGoogle ScholarPubMed
23.Carlton, PL, Goldstein, L. Physiological determinants of pathological gambling. In: Glaski, T, ed. A Handbook of Pathological Gambling. Springfield, Ill: Charles C. Thomas; 1987:657–663.Google Scholar
24.Wender, PH, Reimherr, FW, Wood, DR. Attention-deficit disorder (‘minimal brain dysfunction’) in adults: a replication study of diagnosis and drug treatment. Arch Gen Psychiatry. 1981;38:449–456.Google Scholar
25.Wood, D, Wender, PH, Reimherr, FW. The prevalence of attention deficit disorder, residual type, or minimum brain dysfunction, in a population of male alcoholic patients. Am J Psychiatry. 1983;140:95–98.Google Scholar
26.Carlton, PL, Manowitz, P. Physiological factors as determinants of pathological gambling. J Gambling Behav. 1988;3:274–285.Google Scholar
27.Soubrie, P. Reconciling the role of central serotonin neurons in human and animal behavior. Behav Brain Sci. 1986;9:319–364.Google Scholar
28.Siever, LJ. Role of noradrenergic mechanisms in the etiology of the affective disorders. In: Meltzer, HY, ed. Psychopharmacology: Third Generation of Progress. New York, NY: Raven Press; 1987:493–504.Google Scholar
29.Eichelman, BS, Thoa, NB, Ng, KY. Facilitated aggression in the rat following 6-hydroxydopamine administration. Physiol Behav. 1972;8:1–3.CrossRefGoogle ScholarPubMed
30.Blum, K, Sheridan, PJ, Wood, RC, Braverman, CR, Chen, TJ, Comings, DE. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics. 1995;5:121–144.Google Scholar
31.Robertson, MW, Leslie, CA, Bennett, JP. Apparent synaptic dopamine deficiency induced by withdrawal from chronic cocaine treatment. Brain Res. 1991;538:337–339.CrossRefGoogle ScholarPubMed
32.Routtenberg, A. The reward system of the brain. Sci Am. 1978;239:154–165.Google Scholar
33.Wise, RA, Rompre, PP. Brain dopamine and reward. Annu Rev Psychol. 1989;40:191–225.Google Scholar
34.Koob, GF. Drug of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 1992;13:177–184.CrossRefGoogle ScholarPubMed
35.Geyer, MA, Segal, DS. Shock-induced aggression: opposite effects of intraventricularly infused dopamine and norepinephrine. Behav Biol. 1974;10:99–104.Google Scholar
36.Tork, I. Anatomy of the serotonergic system. Ann NY Acad Sci. 1990;600:9–34.Google Scholar
37.Moreno, I, Saiz-Ruiz, JY, Lopez-Ibor, JJ. Serotonin and gambling dependence. Hum Psychopharmacol. 1991;6:S9–S12.Google Scholar
38.Bertilsson, L, Asberg, M, Thoren, P. Differential effect of chlorimipramine and nortriptyline on cerebrospinal fluid metabolites of serotonin and noradrenaline in depression. Eur J Clin Pharmacol. 1974;7:365–368.CrossRefGoogle ScholarPubMed
39.DeCaria, C, Hollander, E, Nora, R, Stein, D, Simeon, D, Cohen, LGambling: Biological/genetic, treatment, government, and gaming concerns: neurobiology of pathological gambling. Presented at the American Psychiatric Association Annual Meeting; May 1997; San Diego, Calif.Google Scholar
40.Hamik, A, Peroutka, SJ. 1-(m-chlorophenyl) piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry. 1989;25:569–575.Google Scholar
41.Hoyer, D. Functional correlates of serotonin 5-HT1 recognition sites. J Recept Res. 1988;8:59–81.CrossRefGoogle ScholarPubMed
42.Caccia, S, Ballabio, M, Samanin, R, Zanini, MG, Garattini, S. M-CPP, a central 5-HT agonist, is a metabolite of trazodone. J Pharm Pharmacol. 1981;33:477–478.CrossRefGoogle ScholarPubMed
43.Gothert, M, Schlicker, E. Classification of serotonin receptors. J Cardiovasc Pharmacol. 1987;10(suppl 3):S3–S7.Google Scholar
44.Pazos, A, Palacios, JM. Quantitative autoradiography mapping of serotonin receptors in the rat brain. I: serotonin-1 receptors. Brain Res. 1985;346:205–230.CrossRefGoogle Scholar
45.Kennett, GA, Curzon, G. Evidence that hypophagia induced by mCPP and TFMPP requires 5HT1c and 5HT1b receptors; hypophagia induced by RU 24969 only requires 5HT1b receptors. Psychopharmacology. 1988;96:93–100.Google Scholar
46.Kennett, GA, Curzon, G. Evidence that mCPP may have behavioural effects mediated by central 5-HT1c receptors. Br J Pharmacol. 1988;94:137–147.CrossRefGoogle ScholarPubMed
47.Kennett, GA, Whitton, P, Shah, K, Curzon, G. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5HT1c receptor antagonists. Eur J Pharmacol 1989;164:445–454.Google Scholar
48.Quattrone, A, Schettini, G, Annunziato, L, DiRenzo, G. Pharmacological evidence of supersensitivity of central serotonergic receptors involved in the control of prolactin secretion. Eur J Pharmacol. 1981;76:9–13.Google Scholar
49.Moss, HB, Yao, JK, Panzak, GL. Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse. Biol Psychiatry. 1990;28:325–338.Google Scholar
50.Hollander, E, Stein, D, DeCaria, CM, et al.Serotonergic sensitivity in borderline personality disorder: preliminary findings. Am J Psychiatry. 1994;151:277–280.Google ScholarPubMed
51.Stein, DJ, Hollander, E, DeCaria, C, Cohen, L, Simeon, D. Behavioral response to m-chlorophenyl-piperazine and clonidine in trichotillomania. Journal of Serotonin Research. 1997;4:11–15.Google Scholar
52.Benkelfat, C, Murphy, DL, Hill, JL, George, DT, Nutt, D, Linnoila, M. Ethanol like properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. Arch Gen Psychiatry. 1991;48:383. Letter.Google Scholar
53.Levitt, P, Pintar, JE, Braekefield, XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonin neurons. Proc Natl Acad Sci U S A. 1982;70:6385–6389.CrossRefGoogle Scholar
54.Blanco, C, Orensanz-Munoz, L, Bianco-Jerez, C, Saiz-Ruiz, J. Pathological gambling and platelet MAO activity: a psychobiological study. Am J Psychiatry. 1996;153:119–121.Google ScholarPubMed
55.Carrasco, J, Saiz-Ruiz, J, Moreno, I, Hollander, E, Lopez-Ibor, JJ. Low platelet monoamine oxidase activity in pathological gambling. Acta Psychiatr Scand. 1994;90:427–431.Google Scholar
56.Penis, C, Jacobsson, L, von Knorring, L, Oreland, L, Perris, H, Ross, SB. Enzymes related to biogenic amine metabolism and personality characteristics in depressed patients. Acta Psychiatr Scand. 1980;61:477–484.Google Scholar
57.Schalling, D, Asberg, M. Biological and psychological correlates of impulsiveness and monotony avoidance. In: Strelau, J, Farley, FH, Gale, A, eds. The Biological Foundations of Personality and Behavior. New York: Hemisphere Press; 1985:181–194.Google Scholar
58.Murphy, KL, Belmaker, R, Buchsbaum, MS. Biogenic amine related enzymes and personality variations in normals. Psychol Med, 1977;7:149–157.CrossRefGoogle ScholarPubMed
59.von Knorring, L, Oreland, L, Winblad, B. Personality traits related to monoamine oxidase activity in platelets. Psychiatry Res. 1984;12:11–26.Google Scholar
60.Waid, PB, Catts, SV, Norman, TR, Burrows, GD, McConaghy, N. Low platelet monoamine oxidase and sensation seeking in males: an established relationship? Acta Psychiatr Scand. 1987;75:86–90.Google Scholar
61.Buchsbaum, MS, Haier, RJ, Murphy, DL. Suicide attempts, platelet monoamine oxidase and the average evoked response. Acta Psychiatr Scand. 1977:56:69–79.Google Scholar
62.Gottfries, CG, von Knorring, L, Oreland, L. Platelet monoamine oxidase activity in mental disorders. II: Affective psychoses and suicidal behavior. Prog Neuro-Psychopharmacol. 1980;4:185–192.Google Scholar
63.Brunner, HG, Nelen, MR, van Zandvoort, P, et al.X-linked borderline mental retardation with prominent behavioral disturbance: phenotype, genetic localization, and evidence for disturbed monoamine metabolism. Am J Hum Genet. 1993;52:1032–1039.Google ScholarPubMed
64.Krystal, JH, Webb, E, Coony, N, Kranzler, HR, Charney, DS. Specificity of ethanollike effects elicited by serotonergic and noradrenergic mechanisms. Arch Gen Psychiatry. 1994;51:898–911.Google Scholar
65.Meert, TF, Awouters, F, Niemegeers, CJ, Schellekelas, KH, Janssen, PA. Ritanserin reduces abuse of alcohol, cocaine and fentanyl in rats. Pharmacopsychiatry. 1991;24:159–163.Google Scholar
66.Leysen, JE, Gommeren, W, van Gompel, P, Wynants, J, Janssen, PF, Laduron, PM. Receptor-binding properties in vitro and in vivo of ritanserin, a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol. 1985;27:600–611.Google Scholar
67.van de Kar, LD, Rittenhouse, PA, O'Connor, P, et al.Effect of cocaine injections on the neuroendocrine response to the serotonin agonist MK-212. Biol Psychiatry. 1992;32:258–269.Google Scholar
68.Berendsen, JJG, Broekkamp, CLE. Behavioral evidence for functional interactions between 5-HT receptor subtypes in rats and mice. Br J Pharmacol. 1990;101:667–673.Google Scholar
69.Lee, MA, Meltzer, HY. Blunted oral body temperature response to MK-212 in cocaine addicts. Drug Alcohol Depend. 1994;35:217–222.Google Scholar
70.Coccaro, EF, Siever, LJ, Klar, HM, et al.Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive-aggressive behavior. Arch Gen Psychiatry. 1989;46:587–599.CrossRefGoogle ScholarPubMed
71.Linnoila, M, Virkkunen, , Schienin, M, Nuutila, A, Rimon, R, Goodwin, F. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from non-impulsive violent behavior. Life Sci. 1983;33:2609–2614.CrossRefGoogle Scholar
72.Gardner, DL, Lucas, PB, Cowdry, RW. CSF metabolites in borderline personality disorder compared with normal controls. Biol Psychiatry. 1990;28:247–254.Google Scholar
73.Mann, J, McBride, A, Brown, RP, et al.Relationship between central and peripheral serotonin indexes in depressed and suicidal psychiatric inpatients. Arch Gen Psychiatry. 1992;49:442–446.CrossRefGoogle ScholarPubMed
74.Tollefson, GD. Anxiety and alcoholism: a serotonin link. Br J Psychiatry. 1991;159(suppl 2):34–39.Google Scholar
75.Roy, A, Custer, R, Lorenz, V, Linnoila, M. Depressed pathological gamblers. Acta Psychiatr Scand. 1988;77:163–165.Google Scholar
76.Hollander, E, Benzaquen, SD. Is there a distinct OCD spectrum? CNS Spectrum. 1996;1:17–26.CrossRefGoogle Scholar
77.Cloninger, CR. The Tridimensional Personality Questionnaire. St. Louis, Mo: Department of Psychiatry, Washington University School of Medicine; 1987.Google Scholar
78.Hollander, E, DeCaria, C, Nitescu, A, et al.Noradrenergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to clonidine and comparison to healthy controls. Psychiatry Res. 1991;37:161–177.CrossRefGoogle ScholarPubMed
79.Hollander, E. Introduction. In: Hollander, E, ed. Obsessive-Compulsive Related Disorders. Washington DC: American Psychiatric Press; 1993:1–16.Google Scholar
80.DeCaria, C, Hollander, E, Frenkel, M, et al.Pathological gambling: an OCD related disorder? Presented at the 145th Annual Meeting of the American Psychiatric Association; May 1, 1992; Washington, DC.Google Scholar
81.DeCaria, C, Hollander, E. Pathological gambling. In: Hollander, E, ed. Obsessive-Compulsive Related Disorders. Washington, DC: American Psychiatric Press; 1993:155–178.Google Scholar
82.Hollander, E. Obsessive-compulsive spectrum disorders: theory and treatment: gambling and other impulse control disorders. Presented at the 147th Annual Meeting of the American Psychiatric Association; 1994; Philadelphia, Pa.Google Scholar
83.Hollander, E, Wong, CM. Body dysmorphic disorder, pathological gambling, and sexual compulsions. J Clin Psychiatry. 1995;56(suppl 4):7–12.Google Scholar
84.Hollander, E, DeCaria, C, Nitescu, A, et al.Serotonergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to oral m-CPP and fenfluramine in patients and healthy controls. Arch Gen Psychiatry. 1992;49:21–28.Google Scholar
85.Hollander, E, Frenkel, M, DeCaria, C, Trungold, S, Klein, DF. Treatment of pathological gambling with clomipramine. Am J Psychiatry. 1992;149:710–711. Letter.Google Scholar
86.Dresse, A, Scuvee-Moreau, J. The effects of various antidepressants on the spontaneous firing rates of noradrenergic and serotonergic neurons. Clin Neuropharmacol. 1984;7(suppl 1):572–573.Google Scholar
87.Blier, P, deMontigny, C, Chaput, Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclusive evidence. J Clin Psychiatry. 1990;51(suppl 4):14–20.Google Scholar
88.Johnson, AM. Pharmacological properties of selective serotonin reuptake inhibitors. In: Feighner, JP, Boyer, WF, eds. Selective Serotonin Reuptake Inhibitors. Perspectives in Psychiatry. Vol 1. West Sussex, England: John Wiley & Sons; 1991:37–76.Google Scholar
89.Pineyro, G, deMontigny, C, Blier, P. 5-HT1d receptors regulate 5-HT release in the rat raphe nuclei. In vivo voltammetry and in vitro superfusion sutdies. Neuropsychopharmacol. 1995;13:249–260.Google Scholar
90.Racagni, G, Bradford, D. Biochemical and behavioral changes on chronic fluvoxamine administration. CINP Congress; 1984. Florence, Italy: Abstract.Google Scholar
91.Roy, A, DeJong, J, Linnoila, M. Extroversion in pathological gamblers: correlates with indexes of noradrenergic function. Arch Gen Psychiatry. 1989;46:679–681.Google Scholar
92.Fuxe, K, Hokfelt, T, Ungerstedt, U. Morphological and functional aspects of central monoamine neurons. In: Pfeiffer, CC, Smythes, J, eds. International Review of Neurobiology. New York, NY: Academic Press; 1970;13:93–126.Google Scholar
93.Usdin, E, Snyder, S, eds. Frontiers in Catecholamine Research. Elmsford, NY: Pergamon; 1973.Google Scholar
94.Anderson, G, Brown, R. Real and laboratory gambling, sensation-seeking and arousal. Br J Psychology. 1984;75:401–410.Google Scholar
95.Brown, R. Arousal and sensation-seeking components in the general explanation of gambling and gambling addictions. Int J Addict. 1986;21:1001–1016.Google Scholar
96.Boyd, WH. Excitement: the gambler's drug. In: Eadington, WR, ed. Gambling and Society. Springfield, Ill: Charles C. Thomas; 1976.Google Scholar
97.Brown, R. Classical and operant paradigms in the management of gambling addictions. Behav Psychother. 1987;15:111–122.Google Scholar
98.Dickerson, M, Hinchy, J, Falve, J. Chasing, arousal and sensation-seeking in off-course gamblers. Br J Addict. 1987;82:673–680.Google Scholar
99.Kobinger, W, Pichler, L. Centrally induced reduction in sympathetic tone—a postsynaptic alpha-adrenoceptor stimulating action of imidazolines. Eur J Pharmacol. 1976;40:311–320.Google Scholar
100.Eriksson, E, Eden, S, Modigh, K. Up- and down-regulation of central postsynaptic alpha 2 receptors reflected in the growth hormone response to clonidine in reserpine-pretreated rats. Psychopharmacology. 1982;77:327–331.Google Scholar
101.Rudolph, CD, Kaplan, SL, Ganong, WF. Sites at which clonidine acts to affect blood pressure and the secretion of renin, growth hormone and ACTH. Neuroendocrinology. 1980;31:121–128.Google Scholar
102.Lal, S, Tolis, G, Martin, JB, Brown, GM, Guyda, H. Effect of clonidine on growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone and thyroid-stimulating hormone in the serum of normal men. J Clin Endocrinol Metab. 1975;41:827–832.Google Scholar
103.Kruhlich, L, Mayfield, MA, Steele, MK, McMillen, BA, McCann, SM, Koenig, JI. Differential effects of pharmacological manipulations of central alpha 1- and alpha 2-adrenergic receptors on the secretion of thyrotropin and growth hormone in male rats. Endocrinology. 1982;110:796–804.Google Scholar
104.McWilliam, JR, Meldrum, BS. Noradrenergic regulation of growth hormone secretion in the baboon. Endocrinology. 1983;112:254–259.Google Scholar
105.Glass, IB, Checkley, SA, Shur, E, Dawling, S. The effect of desipramine upon central adrenergic function in depressed patients. Br J Psychiatry. 1982;141:372–376.Google Scholar
106.Siever, LJ, Insel, T, Uhde, T. Noradrenergic challenges in the affective disorders. J Clin Psychopharmacol. 1981;l:193–206.Google Scholar
107.Coccaro, EF, Lawrence, T, Trestman, R, Gabriel, S, Klar, HM, Siever, LJ. Growth hormone responses to intravenous clonidine challenge correlates with behavioral irritability in psychiatric patients and healthy volunteers. Psychiatry Res. 1991;39:129–139.Google Scholar
108.Levine, ES, Litto, WJ, Jacobs, BL. Activity of cat locus coeruleus noradrenergic neurons during the defense reaction. Brain Res. 1990;531:189–195.Google Scholar
109.Lamprecht, F, Eichelman, B, Thoa, NB, Williams, RB, Kopin, IF. Rat fighting behavior: serum dopamine-beta-hydroxy-lase and hypothalamic tyrosine hydroxylase. Science. 1972;177:1214–1215.CrossRefGoogle ScholarPubMed
110.McKinney, WT, Moran, EC, Kraemer, GW. Separation in nonhuman primates as a model for human depression: neurobiological implications. In: Post, RM, Ballenger, JC, eds. Neurobiology of Mood Disorders. Baltimore, Md: Williams & Wilkins; 1984.Google Scholar
111.Glassman, AH, Covey, LS, Dalack, GW, et al.Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther. 1993;54:670–679.Google Scholar